These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37950707)

  • 21. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
    Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
    Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
    Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
    Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
    Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
    Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
    Beg MS; Huang X; Silvers MA; Gerber DE; Bolluyt J; Sarode V; Fattah F; Deberardinis RJ; Merritt ME; Xie XJ; Leff R; Laheru D; Boothman DA
    J Surg Oncol; 2017 Jul; 116(1):83-88. PubMed ID: 28346693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.
    Dai B; Augustine JJ; Kang Y; Roife D; Li X; Deng J; Tan L; Rusling LA; Weinstein JN; Lorenzi PL; Kim MP; Fleming JB
    Cell Death Dis; 2021 Jul; 12(7):693. PubMed ID: 34247201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
    Qadir MI; Iqbal MS; Khan R
    Curr Cancer Drug Targets; 2022; 22(7):537-540. PubMed ID: 35490325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer.
    Liu F; Yu G; Wang G; Liu H; Wu X; Wang Q; Liu M; Liao K; Wu M; Cheng X; Hao H
    PLoS One; 2012; 7(7):e42138. PubMed ID: 22848731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel β-carboline-based indole-4,7-quinone derivatives as NAD(P)H: Quinone-oxidoreductase-1 inhibitor with potent antitumor activities by inducing reactive oxygen species, apoptosis, and DNA damage.
    Guo Y; Xu L; Ling C; Yang T; Zheng W; Lv J; Guo Q; Chen B
    Chem Biol Drug Des; 2020 Dec; 96(6):1433-1446. PubMed ID: 32592323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells.
    Du J; Daniels DH; Asbury C; Venkataraman S; Liu J; Spitz DR; Oberley LW; Cullen JJ
    J Biol Chem; 2006 Dec; 281(49):37416-26. PubMed ID: 17040906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
    Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
    J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase.
    Song J; Zou G; Zhao Z; Zhu Y; Xue J; Ao L; Sun H; Hao H; Zhang B; Xu X
    Chin J Nat Med; 2024 Jan; 22(1):75-88. PubMed ID: 38278561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
    Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
    Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation.
    Zhao W; Jiang L; Fang T; Fang F; Liu Y; Zhao Y; You Y; Zhou H; Su X; Wang J; Liu S; Chen Y; Wan J; Huang X
    Front Oncol; 2021; 11():747282. PubMed ID: 34676172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer.
    Zhou L; Chen J; Sun Y; Chai K; Zhu Z; Wang C; Chen M; Han W; Hu X; Li R; Yao T; Li H; Dong C; Shi S
    J Nanobiotechnology; 2021 Sep; 19(1):261. PubMed ID: 34481495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer.
    Starcher CL; Pay SL; Singh N; Yeh IJ; Bhandare SB; Su X; Huang X; Bey EA; Motea EA; Boothman DA
    Front Oncol; 2020; 10():1575. PubMed ID: 32974194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.
    Park MT; Song MJ; Lee H; Oh ET; Choi BH; Jeong SY; Choi EK; Park HJ
    PLoS One; 2011; 6(10):e25976. PubMed ID: 21998736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
    Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
    Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.
    Park EJ; Min KJ; Lee TJ; Yoo YH; Kim YS; Kwon TK
    Cell Death Dis; 2014 May; 5(5):e1230. PubMed ID: 24832602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL; Winski SL; Ross D
    Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.